Compare UCL & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UCL | TIL |
|---|---|---|
| Founded | 2014 | 2018 |
| Country | Hong Kong | United States |
| Employees | N/A | 17 |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.8M | 54.8M |
| IPO Year | 2019 | 2021 |
| Metric | UCL | TIL |
|---|---|---|
| Price | $1.20 | $8.25 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $125.00 |
| AVG Volume (30 Days) | 6.5K | ★ 21.2K |
| Earning Date | 05-20-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 6.06 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.60 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.72 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.10 | $5.67 |
| 52 Week High | $4.19 | $42.75 |
| Indicator | UCL | TIL |
|---|---|---|
| Relative Strength Index (RSI) | 31.69 | 42.33 |
| Support Level | N/A | $7.88 |
| Resistance Level | $1.41 | $9.03 |
| Average True Range (ATR) | 0.07 | 0.54 |
| MACD | -0.00 | -0.05 |
| Stochastic Oscillator | 0.00 | 29.71 |
Ucloudlink Group Inc is engaged in the provision of data connectivity services and sales of Wi-Fi terminals and data related products to enable personal and enterprise users to access mobile internet in more than 100 countries and areas. Leveraging its inventive cloud SIM technology and architecture, the company redefine the mobile data connectivity experience, allowing users to gain access to mobile data traffic allowance shared by network operators on its marketplace. It has aggregated mobile data traffic allowances from 391 MNOs in 163 countries and regions in its cloud SIM architecture. The company derives maximum revenue from Japan.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.